{"id":"W2560331278","doi":"10.1158/1078-0432.ccr-16-1968","title":"Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non–Small Cell Lung Cancer Patients","year":2016,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Nintedanib; Vandetanib; Ramucirumab; Sunitinib; Bevacizumab; Erlotinib; Lung cancer; Oncology; Aflibercept; Sorafenib; Internal medicine; Vascular endothelial growth factor; Population; Cancer; Cancer research; Epidermal growth factor receptor; Hepatocellular carcinoma; Idiopathic pulmonary fibrosis; Lung; Chemotherapy; VEGF receptors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001088826,0.0004277696,0.001609362,0.0001555403,0.0004970724,0.00003913322,0.0004640213,0.0002171801,0.0001563703],"category_scores_gemma":[0.0002947041,0.000161634,0.001173921,0.0006448518,0.0003672512,0.00005663351,0.00008778115,0.0004979005,0.00001411128],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001650261,"about_ca_system_score_gemma":0.002321612,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0015731,"about_ca_topic_score_gemma":0.0009135077,"domain_scores_codex":[0.9963324,0.0003882552,0.001024613,0.0007127087,0.0007929677,0.0007490545],"domain_scores_gemma":[0.9916437,0.005559261,0.0006768696,0.0008889267,0.0009883677,0.0002429205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002585902,0.001264008,0.01807006,0.001996688,0.00579663,0.000005517118,0.0003173465,0.000004144225,8.033345e-8,0.000003738786,0.001551317,0.9707319],"study_design_scores_gemma":[0.006895736,0.003356953,0.01882003,0.01714856,0.01446598,5.15743e-7,0.00006124981,0.0000387315,0.00001046057,0.000007186597,0.9389279,0.0002666134],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02010818,0.9676933,0.00001559435,0.000277242,0.0007706134,0.008734515,0.002210497,0.00001870217,0.0001713873],"genre_scores_gemma":[0.002251071,0.9767144,0.0000203695,0.00003302163,0.0007863418,0.01484167,0.0001767614,0.000125505,0.005050905],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9704652,"threshold_uncertainty_score":0.6591244,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4281299828099905,"score_gpt":0.5598813256620567,"score_spread":0.1317513428520662,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}